# CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA

> **NCT05299476** · PHASE2 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 32 (actual)

## Conditions studied

- Advanced Gastroesophageal Adenocarcinoma
- First-line Therapy
- PDL1 CPS < 5

## Interventions

- **DRUG:** CAPOX combined with bevacizumab and Tislelizumab

## Key facts

- **NCT ID:** NCT05299476
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-25
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-01-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299476, "CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05299476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*